Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH -- Ignore unavailable to you. Want to Upgrade?

To: KurtVedder who wrote (593)	3/10/1998 5:24:00 PM
From: limit	Respond to of 998

Thanks for the info Kurt. Good movement on good volume today and the price held at the close.

To: KurtVedder who wrote (593)	3/10/1998 7:08:00 PM
From: NCKEV	Respond to of 998

your awsum Kurt, thanks for the info..

To: KurtVedder who wrote (593)	3/16/1998 4:25:00 PM
From: Rudy Saucillo	Read Replies (1) \| Respond to of 998

This week's BioCentury has an article entitled, "Myotrophin: What's different this time?" In addition to the changes in membership of the AC, they cite new data provided to the FDA. This new data includes follow-up data from the 2 pivotal trials and analyses of pharmacokinetic and pharmacodynamic data. See also BioCentury Extra, Nov. 12, 1997. I haven't seen any documented reference to the T-IND data, but if the company says it's part of the amended NDA package, we'll hold them to it. IMO, new data outside of the 2 trials and the PK/PD analyses are both necessary to convince the AC of Myo efficacy. Rudy